Jeffrey Edward Nelson Sells 12,245 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) COO Jeffrey Edward Nelson sold 12,245 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $23,632.85. Following the completion of the sale, the chief operating officer owned 49,848 shares in the company, valued at approximately $96,206.64. The trade was a 19.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Jeffrey Edward Nelson also recently made the following trade(s):

• On Monday, December 15th, Jeffrey Edward Nelson sold 58,007 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.32, for a total transaction of $134,576.24.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock traded down $0.07 during mid-day trading on Wednesday, reaching $1.94. The company had a trading volume of 1,697,941 shares, compared to its average volume of 3,110,069. The business has a fifty day simple moving average of $2.23 and a 200 day simple moving average of $1.96. The company has a market cap of $165.23 million, a P/E ratio of -2.37 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. On average, equities research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in MIST. Simplify Asset Management Inc. increased its stake in shares of Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in Milestone Pharmaceuticals by 553.5% during the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after acquiring an additional 110,699 shares in the last quarter. Bay Rivers Group grew its holdings in Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares during the period. Boxer Capital Management LLC bought a new stake in Milestone Pharmaceuticals in the third quarter valued at $1,333,000. Finally, Aptus Capital Advisors LLC bought a new stake in Milestone Pharmaceuticals in the third quarter valued at $420,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MIST has been the subject of several recent research reports. Wells Fargo & Company upped their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

More Milestone Pharmaceuticals News

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.